“`html
On November 7, 2025, Chardan Capital reaffirmed its Buy recommendation for Intellia Therapeutics (NasdaqGM:NTLA). The average one-year price target is set at $33.78/share, indicating a potential increase of 254.79% from its latest closing price of $9.52/share, with projections ranging from a low of $8.08 to a high of $111.30.
Intellia Therapeutics is projected to achieve annual revenue of $126 million, an increase of 119.86%. The company’s projected annual non-GAAP EPS stands at -6.24. Institutional ownership has decreased by 5.05% over the last three months, with total shares owned at 120,404K.
Currently, 497 funds report positions in Intellia Therapeutics, with an average portfolio weight of 0.09%. Notable shareholders include ARK Investment Management with 13,018K shares (12.13% ownership) and Regeneron Pharmaceuticals holding 3,703K shares (3.45% ownership).
“`
